» Articles » PMID: 39361110

PET Radiomics in Lung Cancer: Advances and Translational Challenges

Overview
Journal EJNMMI Phys
Specialty Radiology
Date 2024 Oct 3
PMID 39361110
Authors
Affiliations
Soon will be listed here.
Abstract

Radiomics is an emerging field of medical imaging that aims at improving the accuracy of diagnosis, prognosis, treatment planning and monitoring non-invasively through the automated or semi-automated quantitative analysis of high-dimensional image features. Specifically in the field of nuclear medicine, radiomics utilizes imaging methods such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) to evaluate biomarkers related to metabolism, blood flow, cellular activity and some biological pathways. Lung cancer ranks among the leading causes of cancer-related deaths globally, and radiomics analysis has shown great potential in guiding individualized therapy, assessing treatment response, and predicting clinical outcomes. In this review, we summarize the current state-of-the-art radiomics progress in lung cancer, highlighting the potential benefits and existing limitations of this approach. The radiomics workflow was introduced first including image acquisition, segmentation, feature extraction, and model building. Then the published literatures were described about radiomics-based prediction models for lung cancer diagnosis, differentiation, prognosis and efficacy evaluation. Finally, we discuss current challenges and provide insights into future directions and potential opportunities for integrating radiomics into routine clinical practice.

Citing Articles

Study on postoperative survival prediction model for non-small cell lung cancer: application of radiomics technology workflow based on multi-organ imaging features and various machine learning algorithms.

Wang H, Hong Y, Zhang Z, Cheng K, Chen B, Zhang R Front Med (Lausanne). 2025; 12:1517765.

PMID: 39975681 PMC: 11835680. DOI: 10.3389/fmed.2025.1517765.


The Impact of Bone Marrow Involvement on Prognosis in Diffuse Large B-Cell Lymphoma: An 18F-FDG PET/CT Volumetric Segmentation Study.

Doma A, Studen A, Novakovic B Cancers (Basel). 2024; 16(22).

PMID: 39594717 PMC: 11592337. DOI: 10.3390/cancers16223762.

References
1.
Leithner D, Schoder H, Haug A, Vargas H, Gibbs P, Haggstrom I . Impact of ComBat Harmonization on PET Radiomics-Based Tissue Classification: A Dual-Center PET/MRI and PET/CT Study. J Nucl Med. 2022; 63(10):1611-1616. PMC: 9536705. DOI: 10.2967/jnumed.121.263102. View

2.
Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C . LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018; 78(16):4786-4789. DOI: 10.1158/0008-5472.CAN-18-0125. View

3.
Lucia F, Louis T, Cousin F, Bourbonne V, Visvikis D, Mievis C . Multicentric development and evaluation of [F]FDG PET/CT and CT radiomic models to predict regional and/or distant recurrence in early-stage non-small cell lung cancer treated by stereotactic body radiation therapy. Eur J Nucl Med Mol Imaging. 2023; 51(4):1097-1108. DOI: 10.1007/s00259-023-06510-y. View

4.
Nemoto H, Saito M, Satoh Y, Komiyama T, Marino K, Aoki S . Evaluation of the performance of both machine learning models using PET and CT radiomics for predicting recurrence following lung stereotactic body radiation therapy: A single-institutional study. J Appl Clin Med Phys. 2024; 25(7):e14322. PMC: 11244675. DOI: 10.1002/acm2.14322. View

5.
Dingemans A, Fruh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks L . Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(7):839-853. PMC: 9464246. DOI: 10.1016/j.annonc.2021.03.207. View